Sugi Predict

Sugi Predict / Compounds / SCHEMBL25753072

SCHEMBL25753072

SCHEMBL25753072

COc1c(NC(=O)OC(C)(C)C)ccc2cnn(C(C)C)c12

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PIK3CD O00329 2/20 0.42
▸ ABL1 P00519 2/20 0.42
▸ EGFR P00533 2/20 0.42
▸ KDR P35968 2/20 0.42
▸ PIK3CA P42336 2/20 0.42
▸ PIK3CG P48736 2/20 0.42
▸ PRKDC P78527 2/20 0.42
▸ BACE1 P56817 1/20 0.42
▸ PI4KB Q9UBF8 1/20 0.42
▸ GSK3B P49841 1/20 0.36
▸ DYRK1A Q13627 1/20 0.36
▸ MAPK1 P28482 1/20 0.35
▸ HCK P08631 1/20 0.35
▸ SRC P12931 1/20 0.35
▸ PIK3CB P42338 1/20 0.35
▸ MTOR P42345 1/20 0.35
▸ EPHB4 P54760 1/20 0.35
▸ ELANE P08246 1/20 0.35
▸ CTRB1 P17538 1/20 0.35
▸ ABCB1 P08183 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30895051 0.92 PIK3CD (0.39) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL25757760 0.88 PIK3CD (0.36) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL30860930 0.85 GSK3B (0.40) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL25756633 0.85 GSK3B (0.40) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL27199549 0.84 MAPK1 (0.40) MAPK1PDE9ATSHR
SCHEMBL30895136 0.82 GSK3B (0.36) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL31017447 0.82 GSK3B (0.36) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL25672474 0.82 MAPK1 (0.39) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL25753440 0.81 GSK3B (0.38) PIK3CDABL1EGFRKDRPIK3CA
SCHEMBL30895022 0.81 HTR2A (0.36) PIK3CDABL1EGFRKDRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO LTD (CN) 2025-04-10 — — US disclosed
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-10-29 — — US disclosed
CN-118401516-A TYK2 inhibitors, compositions and methods thereof 凌科药业(杭州)有限公司 2024-07-26 — — CN disclosed
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2024-04-18 — — US disclosed
WO-2023109954-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF LYNK PHARMACEUTICALS CO. LTD. (CN) 2023-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124448-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 PIK3CD 732/4885ABL1 6/4885EGFR 804/4885
US-20250115597-A1 TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF TYK2, JAK2, JAK1 PIK3CD 732/4885ABL1 6/4885EGFR 804/4885
US-12129250-B2 TYK2 inhibitors and compositions and methods thereof TYK2, JAK2, JAK1 PIK3CD 732/4885ABL1 6/4885EGFR 804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.